Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR 62.05
+2.93 (4.96%)
At close: Aug 29, 2025
Concord Drugs Revenue
Concord Drugs had revenue of 136.06M INR in the quarter ending June 30, 2025, with 16.36% growth. This brings the company's revenue in the last twelve months to 471.58M, down -1.00% year-over-year. In the fiscal year ending March 31, 2025, Concord Drugs had annual revenue of 452.45M with 0.71% growth.
Revenue (ttm)
471.58M
Revenue Growth
-1.00%
P/S Ratio
1.32
Revenue / Employee
2.55M
Employees
185
Market Cap
620.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 452.45M | 3.20M | 0.71% |
| Mar 31, 2024 | 449.25M | -71.56M | -13.74% |
| Mar 31, 2023 | 520.81M | -69.62M | -11.79% |
| Mar 31, 2022 | 590.43M | 75.99M | 14.77% |
| Mar 31, 2021 | 514.44M | 165.40K | 0.03% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Hindustan Unilever | 639.28B |
| Infosys | 1,672.76B |
Concord Drugs News
- 8 months ago - Concord Drugs Q3FY25 Results: Revenue declines 15.53% YoY to Rs 10.79 crore - Business Upturn